How America’s former steel heartland secured a $3.5bn Eli Lilly facility

Surveying Lehigh Valley’s humanities concern sites on the Lehigh River evokes a bygone epoch erstwhile the portion was location to 1 of the world’s largest alloy producing hubs. Today, caller investments constituent to a caller manufacturing renaissance, driven by a strategical pivot into beingness sciences.

The zenith of this turnaround arrived erstwhile Eli Lilly selected Lehigh Valley, an country successful eastbound Pennsylvania, for a caller $3.5bn installation to nutrient the drugmaker’s forthcoming question of value nonaccomplishment therapies.

The concern marked the largest of its benignant from the beingness sciences assemblage successful Pennsylvania’s history. With the US value nonaccomplishment marketplace forecast to beryllium worthy $148.7bn by 2031 – the twelvemonth the installation is slated to beryllium operational – Lehigh Valley is acceptable to play a captious relation successful gathering the medicine demand.

Speaking during the announcement successful January 2026, Pennsylvania’s politician Josh Shapiro said: “We’re poised for explosive innovation and maturation successful the beingness sciences manufacture — and that’s precisely wherefore Eli Lilly chose america for their $3.5bn investment.”

For Lehigh Valley Economic Development Corporation’s (LVEDC) CEO, Don Cunningham, the enactment had been going connected down the scenes for a while. The process started successful the summertime of 2024, erstwhile the assemblage – liable for attracting caller companies to the portion – began courting Eli Lilly for a antithetic pharma facility.

“We did a clump of information dives into wherever radical worked, what their accomplishment sets were, wherever they lived, and past began moving with assemblage colleges astir a method grooming pathway that would quadrate with Lilly,” Cunningham tells Pharmaceutical Technology.

“We truly doubled down connected the workforce aspect. We knew that we had a important magnitude of pharma talent.”

Ultimately, Lehigh Valley would autumn abbreviated successful its efforts for the archetypal plant. Despite making it to the last 2 shortlisted candidates, Lilly awarded the declaration to chap mid-Atlantic authorities Virginia. Plans were revealed successful September 2025, with Lilly choosing to physique an progressive pharmaceutical constituent (API) and cause merchandise installation astatine the site. It marked the archetypal announcement of 4 caller mega manufacturing facilities the drugmaker intends to physique successful the US arsenic portion of a $27bn concern drive.

“Lilly said the mode we reacted to not winning the archetypal task was precise helpful. We knew determination were different facilities that had not been announced. And Lilly’s tract enactment folks were already acquainted with our site,” Cunningham says.

Lehigh Valley was palmy 2nd clip round, beating much than 300 different applicants. In a statement, Lilly said it selected the tract successful Fogelsville for its proximity to STEM universities, robust method manufacturing economy, and established infrastructure. Additionally, the pharma elephantine highlighted the region’s convenient entree to utilities and transportation, arsenic good arsenic its favourable zoning and concern incentives.